Back

Development of semisynthetic blasticidin S analogs with potent and fast-killing anti-malarial activity

Fike, K. R.; Gannett, C.; Kiselka, A. M.; Tiller, K.; Ajasa, T.; Weger-Lucarelli, J.; Brown, A. M.; Lowell, A. N.; Klemba, M.

2026-04-13 microbiology
10.64898/2026.04.12.718010 bioRxiv
Show abstract

Protein synthesis represents an attractive target space for the development of anti-malarials with novel modes of action. Natural-product inhibitors of the eukaryotic 80S ribosome can have potent anti-malarial activity but are often poorly selective due to mammalian cytotoxicity. Blasticidin S (BlaS) is a microbially-produced natural product that broadly inhibits prokaryotic and eukaryotic protein synthesis by binding to the ribosomal peptidyl transferase center. In this study, we explored the potential for improving the anti-malarial potency and selectivity of the blasticidin S scaffold with semi-synthetic analogs that are modified at the C6 and C4 sites. The two best analogs were two orders of magnitude more potent than BlaS against Plasmodium falciparum drug-sensitive and -resistant lines while displaying low cytotoxicity towards mammalian cells. These analogs exhibited improved kinetics of inhibition of protein synthesis in cultured parasites and blocked the development of asexual stages expressing the plasmodial surface anion channel, a transporter required for nutrient acquisition and BlaS uptake. They also exhibited a dramatically improved speed of killing over BlaS. Molecular docking analysis revealed that these analogs are able to form more interactions with the P. falciparum ribosomal peptidyl transferase center than is BlaS, which is consistent with their increased potency. Together, these studies demonstrate the feasibility of generating BlaS analogs with potent anti-malarial activity and provide a roadmap for further development.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Journal of Medicinal Chemistry
68 papers in training set
Top 0.1%
12.2%
2
ACS Infectious Diseases
74 papers in training set
Top 0.1%
12.2%
3
ChemMedChem
15 papers in training set
Top 0.1%
8.1%
4
ACS Chemical Biology
150 papers in training set
Top 0.2%
6.8%
5
Cell Chemical Biology
81 papers in training set
Top 0.4%
6.3%
6
Antimicrobial Agents and Chemotherapy
167 papers in training set
Top 0.5%
4.8%
50% of probability mass above
7
ACS Medicinal Chemistry Letters
16 papers in training set
Top 0.1%
3.9%
8
eLife
5422 papers in training set
Top 26%
3.6%
9
mBio
750 papers in training set
Top 5%
3.6%
10
Scientific Reports
3102 papers in training set
Top 50%
2.1%
11
Biomedicine & Pharmacotherapy
43 papers in training set
Top 0.3%
2.1%
12
Nature Communications
4913 papers in training set
Top 49%
1.9%
13
ACS Omega
90 papers in training set
Top 2%
1.7%
14
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 36%
1.3%
15
European Journal of Medicinal Chemistry
16 papers in training set
Top 0.1%
1.3%
16
Journal of Chemical Information and Modeling
207 papers in training set
Top 2%
1.2%
17
The American Journal of Tropical Medicine and Hygiene
60 papers in training set
Top 3%
0.9%
18
Molecules
37 papers in training set
Top 1%
0.9%
19
Frontiers in Microbiology
375 papers in training set
Top 8%
0.9%
20
Chemical Science
71 papers in training set
Top 2%
0.9%
21
PLOS ONE
4510 papers in training set
Top 66%
0.8%
22
PLOS Neglected Tropical Diseases
378 papers in training set
Top 5%
0.8%
23
The Lancet Infectious Diseases
71 papers in training set
Top 3%
0.8%
24
Journal of Natural Products
11 papers in training set
Top 0.2%
0.8%
25
Pharmaceuticals
33 papers in training set
Top 2%
0.7%
26
Malaria Journal
48 papers in training set
Top 2%
0.7%
27
iScience
1063 papers in training set
Top 38%
0.6%
28
Journal of Biological Chemistry
641 papers in training set
Top 5%
0.6%
29
ACS Pharmacology & Translational Science
40 papers in training set
Top 1%
0.6%